Incyte Corporation has acquired Ariad Pharmaceuticals’ European operations for $140 million. The companies also agreed to enter into a license agreement that gives Incyte an exclusive license to develop and commercialize Iclusig (ponatinib) in Europe and other select countries. The planned acquisition of a fully-integrated and established pan-European team of 125 employees, including medical, sales and marketing personnel, will further Incyte’s strategic plan and accelerate the establis...